These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30276543)

  • 1. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer.
    Moschini M; Zaffuto E; Karakiewicz P; Mattei A; Gandaglia G; Fossati N; Montorsi F; Briganti A; Shariat SF
    World J Urol; 2019 Jun; 37(6):1127-1135. PubMed ID: 30276543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
    Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
    Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
    BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
    Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies.
    Wallner LP; Wang R; Jacobsen SJ; Haque R
    Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):313-6. PubMed ID: 23292083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
    Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
    J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
    Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
    Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
    Baik SH; Kury FSP; McDonald CJ
    J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.
    Dell'Oglio P; Bandini M; Leyh-Bannurah SR; Tian Z; Trudeau V; Larcher A; Fossati N; Moschini M; Gandaglia G; Capitanio U; Briganti A; Graefen M; Montorsi F; Saad F; Karakiewicz PI
    Urol Oncol; 2018 May; 36(5):239.e9-239.e15. PubMed ID: 29426698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.
    Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
    Urol Oncol; 2018 May; 36(5):241.e1-241.e6. PubMed ID: 29503141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
    Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
    PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
    Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
    BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
    Wallander M; Axelsson KF; Lundh D; Lorentzon M
    Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
    Bárcena PGQ; Aprikian AG; Dragomir A
    Cancer Med; 2024 Feb; 13(3):e6922. PubMed ID: 38351647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.